Browse
Submit Data
Databases
API
Help

Dataset Information

7 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A multicentre, randomised, double-blind, placebo-controlled, dose-finding phase II clinical study to evaluate the efficacy of two different doses of MT-102 administered over a sixteen week period in subjects with cachexia related to stage III and IV non-small cell lung cancer and colorectal cancer

ABSTRACT: Intervention1: MT-102: 1x 2.5mg tablet of MT-102 two times per day 1x 2.5mg tablet of MT-102 + 1 placebo tablet two times per day 1x 2.5mg tablet of MT-102 + 3 placebo tablet two times per day 1 x 2.5mg tablet of MT-102 two times per day 2x 2.5mg tablet of MT-102 two times per day 4 x 2.5mg tablets of MT-102 two times per day Control Intervention1: Placebo: 1x placebo tablet two times per day 2x placebo tablet two times per day 4x placebo tablet two times per day Primary outcome(s): Demonstrate the effect of a 10mg / bd dose of MT-102 in comparison to placebo on the rate of weight change over a sixteen week periodTimepoint: Day 7, 14, 21, 28, 56, 84, 112 and 140. Study Design: Randomized, Parallel Group, Placebo Controlled Trial Method of generating randomization sequence:Stratified randomization Method of allocation concealment:Centralized Blinding and masking:Participant, Investigator, Outcome Assessor and Date-entry Operator Blinded

DISEASE(S): Patients With Cachexia Related To Stage Iii And Iv Non-small Cell Lung Cancer And Colorectal Cancer

PROVIDER: 2572880 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Phase II study of TAS-102 in patients with metastatic colorectal cancer

Project description:Intervention name : TAS-102 Dosage And administration of the intervention : TAS-102 70 mg/m2 was administered orally twice a day for 5 days followed by 2 day rest and repeated two times this procedure. Control intervention name : Placebo Dosage And administration of the control intervention : Placebo was administered orally twice a day for 5 days followed by 2 day rest and repeated two times this procedure. Primary outcome(s): Overall survival To evaluate the overall survivals of TAS-102 versus placebo in patients with chemotherapy-refractory metastatic colorectal cancer Study Design: Randomized, double-blind, placebo-controlled, parallel-group comparative study

| 2610203 | ecrin-mdr-crc

Phase II study of TAS-102 in patients with metastatic colorectal cancer

Project description:Interventions: investigational material(s) Generic name etc : TAS-102 INN of investigational material : Therapeutic category code : 422 Antimetabolic agents Dosage and Administration for Investigational material : TAS-102 70 mg/m2 was administered orally twice a day for 5 days followed by 2 day rest and repeated two times this procedure. control material(s) Generic name etc : Placebo INN of investigational material : Therapeutic category code : --- Other Dosage and Administration for Investigational material : Placebo was administered orally twice a day for 5 days followed by 2 day rest and repeated two times this procedure. Primary outcome(s): Overall survival To evaluate the overall survivals of TAS-102 versus placebo in patients with chemotherapy-refractory metastatic colorectal cancer Study Design: Randomized, double-blind, placebo-controlled, parallel-group comparative study

| 99901 | ecrin-mdr-crc

Expression data from RU486 treated FVB wild-type and MMTV- PAX8PPARg mouse mammary tumors

Project description:To determine if RU-486 would be effective as a chemopreventive agent, microarrays were used to analyse global gene expression changes in wild-type vs. MMTV-PAX8PPARg mice to determine their differential response to RU486 RNA was isolated (RNeasy Mini Kit, Qiagen) from progestin/DMBA induced mammary tumors from wi transgenic and wild-type mice treated with placebo or 2.5mg RU486 60-day release pellets

2012-04-29 | E-GEOD-33753 | biostudies-arrayexpress

Neoadjuvant anastrozole alone or with gefitinib in early breast cancer

Project description:Trial 223 was a placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer. We used patients from arm B and C: anastrozole 1mg/d for the duration of the 16 week period plus placebo 1 tablet/d orally for 2 weeks. Patients in arm B were followed by gefitinib 250mg/d orally for 14 weeks whereas patients in arm C continued with placebo for 14 weeks.

2014-01-08 | GSE48906 | GEO

Neoadjuvant anastrozole alone or with gefitinib in early breast cancer

2014-01-08 | E-GEOD-48906 | biostudies-arrayexpress

Molecular classification of the placebo effect in nausea by mass spectrometry

Project description:In this proof-of-concept study, we tested whether placebo effects can be monitored and predicted by plasma proteins. In a randomized controlled design, 90 participants were exposed to a nauseating stimulus on two separate days and were randomly allocated to placebo treatment or no treatment on the second day. Significant placebo effects on nausea, motion sickness, and gastric activity could be verified. Using state-of-the-art proteomics, 74 differentially regulated proteins were identified as correlates of the placebo effect. Gene ontology (GO) enrichment analyses identified acute-phase proteins and microinflammatory proteins to be involved, and the identified GO signatures predicted day-adjusted scores of nausea indices in the placebo group. We also performed GO enrichment analyses of specific plasma proteins predictable by the experimental factors or their interactions and identified ‘grooming behavior’ as a prominent hit. Finally, Receiver Operator Characteristics allowed to identify plasma proteins differentiating placebo responders from non-responders, comprising immunoglobulins and proteins involved in oxidation reduction processes and complement activation. Plasma proteomics are a promising tool to identify molecular correlates and predictors of the placebo effect in humans.

2020-11-13 | PXD020563 | Pride

Effect of turmeric extract in patients with colon cancer

Project description:Intervention1: Tab. Curcuma longa 550 mg: Tab. Curcuma longa 550 mg, 3 times a day daily from the day of initiation of chemotherapy to 8 cycles along with the CAPOX regimen Control Intervention1: Tab. Placebo: Tab. Placebo, 3 times a day daily from the day of initiation of chemotherapy to 8 cycles along with the CAPOX regimen Primary outcome(s): objective response rate (ORR) at the end of 8 cycles of treatment in metastatic colorectal patientsTimepoint: 0 cycle, 8 cycles of chemotherapy Study Design: Randomized, Parallel Group, Placebo Controlled Trial Method of generating randomization sequence:Permuted block randomization, variable Method of allocation concealment:Sequentially numbered, sealed, opaque envelopes Blinding and masking:Participant and Investigator Blinded

| 2758009 | ecrin-mdr-crc

Chronic Prenatal Delta-9-tetrahydrocannabinol Exposure Adversely Impacts Placental Function and Development in a Rhesus Macaque Model

Project description:To investigate the impact of THC exposure on placenta RNA/gene expression Edibles were administered prior to the animal’s daily chow to ensure consumption on an empty stomach and to confirm complete ingestion. Animals were slowly titrated up to 2.5mg/7kg/day of THC using published weight-based medical cannabis acclimation recommendations approximately 4 months prior to undergoing time-mated breeding. Each THC-exposed pregnant animal (n=5) continued to consume a daily edible of 2.5mg/7kg/day throughout pregnancy.

2022-10-24 | GSE216112 | GEO

Chronic Prenatal Delta-9-tetrahydrocannabinol Exposure Adversely Impacts DNA methylation in a Rhesus Macaque Model [methylation]

Project description:Epigenome-wide profiling of DNAm in samples obtained from 10 rhesus macaques Edibles were administered prior to the animal’s daily chow to ensure consumption on an empty stomach and to confirm complete ingestion. Animals were slowly titrated up to 2.5mg/7kg/day of THC using published weight-based medical cannabis acclimation recommendations approximately 4 months prior to undergoing time-mated breeding. Each THC-exposed pregnant animal (n=5) continued to consume a daily edible of 2.5mg/7kg/day throughout pregnancy.

2023-09-11 | GSE223825 | GEO

Effect of a drug (Oral Ivabradine) on BP and Heart Rate during putting endotracheal tube with laryngoscopy.

Project description:Intervention1: Tablet Ivabradine: Oral Ivabradine 5mg was given one hour before surgery Control Intervention1: tablet multivitamin: oral multivitamin(one tablet) one hour before surgery Primary outcome(s): Haemodynamics changesTimepoint: up to 10 min after laryngoscopy and intubation Study Design: Randomized, Parallel Group, Placebo Controlled Trial Method of generating randomization sequence:Computer generated randomization Method of allocation concealment:Sequentially numbered, sealed, opaque envelopes Blinding and masking:Participant, Investigator and Outcome Assessor Blinded

| 2757961 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data